Related Experiment Videos
Folic acid supplementation does not prevent ribavirin-induced anemia
Henry González1, María E Ríos, Esther A Torres
1Department of Medicine A-838, University of Puerto Rico School of Medicine, PO Box 365067, San Juan, PR 00936-5067.
Puerto Rico Health Sciences Journal
|February 11, 2004
Summary
Folic acid supplementation did not prevent anemia caused by ribavirin treatment for hepatitis C. This study found no beneficial effect of folic acid in patients undergoing interferon and ribavirin therapy.
Area of Science:
- Hepatology
- Hematology
- Pharmacology
Background:
- Chronic hepatitis C treatment commonly involves interferon and ribavirin.
- Ribavirin-induced hemolytic anemia is a significant adverse effect that can limit treatment efficacy.
- Folic acid is sometimes used to enhance red blood cell production in hemolytic anemias.
Purpose of the Study:
- To assess the efficacy of folic acid supplementation in preventing anemia associated with ribavirin therapy for hepatitis C.
- To determine if folic acid impacts hemoglobin levels or hemolysis markers in patients treated with ribavirin.
Main Methods:
- A clinical study comparing patients receiving folic acid (1 mg daily) with a control group not receiving supplementation.
- Groups were matched for age, gender, ribavirin dosage, and baseline hemoglobin levels.
- Hemoglobin decrease and hemolysis parameters were monitored in both groups.
Main Results:
- Folic acid supplementation showed no significant effect on the decrease in hemoglobin levels.
- No improvement was observed in measured parameters of hemolysis with folic acid.
- No differences in hemoglobin decrease or nadir hemoglobin levels were noted between males and females.
Conclusions:
- Folic acid supplementation was ineffective in preventing ribavirin-induced anemia in patients treated for hepatitis C.
- The study did not support the use of folic acid to mitigate ribavirin's hematologic side effects.